RADX Company Profile and Key Details

NASDAQ : RADX

Radiopharm Theranostics

$2.00

-0.01-0.50%

Open: 9:55 AM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Radiopharm Theranostics Limited (RADX) stock declined over -0.50%, trading at $2.00 on NASDAQ, down from the previous close of $2.01. The stock opened at $2.00, fluctuating between $1.85 and $2.00 in the recent session.

Stock Snapshot

2.01

Prev. Close

2.58M

Market Cap

1.85

Day Low

-0.34

P/E Ratio

-5.9389

EPS (TTM)

N/A

Cash Flow per Share

Open

1.29M

Number of Shares

Day High

63.62%

Free Float in %

N/A

Book Value

17.37K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 14, 2026	2.01	2.08	1.97	2.01	58.51K
Sep 11, 2026	2.06	2.09	1.98	1.98	37.6K
Sep 10, 2026	2.11	2.28	2.05	2.06	21.99K
Sep 09, 2026	2.15	2.47	2.05	2.08	73.85K
Sep 08, 2026	2.08	2.30	2.06	2.12	27.66K
Sep 04, 2026	2.05	2.15	2.05	2.08	7.91K
Sep 03, 2026	2.27	2.27	2.05	2.16	18.81K
Sep 02, 2026	2.27	2.30	2.05	2.16	11.01K
Sep 01, 2026	2.27	2.27	2.18	2.27	14.58K
Aug 31, 2026	2.37	2.44	2.19	2.28	48.73K
Aug 28, 2026	2.46	2.72	2.27	2.41	333.28K
Aug 27, 2026	2.18	2.33	2.04	2.26	106.8K
Aug 26, 2026	2.43	2.53	2.32	2.32	21.67K
Aug 25, 2026	2.42	2.54	2.34	2.48	34.71K
Aug 24, 2026	2.43	2.52	2.35	2.44	73.07K
Aug 21, 2026	2.36	2.52	2.30	2.44	48.85K
Aug 20, 2026	2.45	2.45	2.23	2.29	88.91K
Aug 19, 2026	2.65	2.71	2.45	2.50	92.87K
Aug 18, 2026	2.66	2.79	2.55	2.62	39.47K
Aug 17, 2026	2.56	2.75	2.51	2.67	60.66K

Contact Details

Carlton, VIC 3053

Australia

https://www.radiopharmtheranostics.com 613 982 45254

About Company

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Stock Peers

ARGX

6.15+0.62%

argenx SE$990.54 REGN

12.25+1.57%

Regeneron Pharmaceuticals, Inc.$793.74 MDGL

5.57+1.04%

Madrigal Pharmaceuticals, Inc.$540.06 VRTX

4.07+0.79%

Vertex Pharmaceuticals Incorporated$519.51 UTHR

5.59+1.12%

United Therapeutics Corporation$502.70 ONC

7.32+2.11%

BeOne Medicines AG$353.83 KRYS

-6.97-2.01%

Krystal Biotech, Inc.$340.03 PRAX

-4.03-1.20%

Praxis Precision Medicines, Inc.$330.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-3.82-1.34%

Ligand Pharmaceuticals Incorporated$280.65

Company Overview

Radiopharm Theranostics Limited (NASDAQ:RADX) closed at $2.00 USD, losing -$0.01 (-0.50%) from the previous close of $2.01. The stock is currently mid-range between its 52-week high and low $1.85 and $16.25. With a market capitalization of about $2.58 million, Radiopharm Theranostics Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~0.80). Key stats such as the average daily volume over the past year has been around 74.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Carlton, VIC, Radiopharm Theranostics Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Riccardo Canevari, the company employs approximately 14 people and listed since December 05, 2024. Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.08%, SMA50 -4.27%, SMA200 -2.52%). The stock’s 14-day RSI is 49.09 (neutral), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.35% below its high and over 42.44% above its low. Average 10-day trading volume of 43.92 thousand shares is below the 3-month average of 75.23 thousand, indicating normal recent market interest.

Valuation Metrics

Radiopharm Theranostics Limited trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 1.35 The P/FCF stands at -0.17, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Radiopharm Theranostics Limited generated EPS of -$3.47 over the past year. Five-year average earnings growth is -71.93%. Wall Street analysts project EPS growth of 20.56% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $15.00. The high target offers 696.02% upside. The low target suggests 646.27% downside. The mean target is $15.67. This offers 679.6% upside. Radiopharm Theranostics Limited earnings surprise history is a mixed track record. The quarter that ended August 28, 2026, missed forecasts by 0.0%. The prior quarter beat by 49.01%. Over the last six quarters, Apple has recorded several small beats. These include 49.01% in February 26, 2026.

Shareholding & Insider Activity

Radiopharm Theranostics Limited has 7.88 million shares outstanding. The public float is 9.08 million shares, elevated short interest at 1.18% of float. This equals 74.10 thousand shares. The short ratio is 0.64 days. Institutional investors hold 2.54% of the float. Insiders own 0.0%.

Financial & Profitability Overview

Over the trailing twelve months, Radiopharm Theranostics generated $2.77M in revenue, or $0.00 per share. Gross margin was -77.67%, operating margin -2468.61%, and net profit margin -1992.46%. Returns are negative, with ROA at -91.71% and ROE at -223.39%.
On valuation metrics, Radiopharm Theranostics trades at a P/E of -0.00, P/S of 1.35 and P/B of 0.00. The current ratio is 1.16 and quick ratio is 1.16. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 1784.54 days.

Quarterly Financial Highlights

Gross profit was - $2.15M (margin -77.67%). Operating income was - $68.33M (margin -2468.6%). Net income was- $55.15M (EPS - $0.02).
The company ended the quarter with $4.14M in cash and short-term investments, a total debt of $0.00, and net debt of - $4.14M. Total assets were $60.13M, with equity of $22.32M. Financials further reflected weakness, with operating cash flow of - $52.78M, free cash flow of $0.00, and capital expenditures of $52.78M.

Price Forecast & Outlook

Our AI price prediction model suggests that Radiopharm Theranostics Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.93%, with price expected at $1.73 by September 28, 2026, within a range of $1.63 to $1.83 3-Month Outlook: Projected fall of -46.77%, reaching $1.07 by December 11, 2026, with a range of $0.81 to $1.25. 1-Year Outlook: Projected loss of -95.02%, with price at $0.10 by September 14, 2027, within a range of $0.00 to $0.20.

Key Takeaways

Radiopharm Theranostics Limited (NASDAQ:RADX) shares are flat -4.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Radiopharm Theranostics Limited trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.00, suggesting 696.02% upside. Our AI forecast model points to short-term weakness (-13.93% over two weeks), a medium-term fall (-46.77% over three months), and a longer-term loss (-95.02% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Radiopharm Theranostics Limited (RADX) stock price?

Radiopharm Theranostics Limited (NASDAQ: RADX) stock price is $2.00 in the last trading session. During the trading session, RADX stock reached the peak price of $2.00 while $1.85 was the lowest point it dropped to. The percentage change in RADX stock occurred in the recent session was -0.5% while the dollar amount for the price change in RADX stock was - $0.01.

RADX's industry and sector of operation?

The NASDAQ listed RADX is part of Biotechnology industry that operates in the broader Healthcare sector. Radiopharm Theranostics Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RADX?

No Data

How RADX did perform over past 52-week?

RADX's closing price is 2.03% higher than its 52-week low of $1.85 where as its distance from 52-week high of $16.25 is -87.63%.

How many employees does RADX have?

Number of RADX employees currently stands at 14.

Link for RADX official website?

Official Website of RADX is: https://www.radiopharmtheranostics.com

How do I contact RADX?

RADX could be contacted at phone 613 982 45254 and can also be accessed through its website. RADX operates from 62 Lygon Street, Carlton, VIC 3053, Australia.

How many shares of RADX are traded daily?

RADX stock volume for the day was 17.37K shares. The average number of RADX shares traded daily for last 3 months was 74.6K.

What is the market cap of RADX currently?

The market value of RADX currently stands at $2.58M with its latest stock price at $2.00 and 1.29M of its shares outstanding.

Employees	14
Beta	0.8
Sales or Revenue	$2.77M
5Y Sales Change%	0%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

RADX Company Profile and Key Details

Radiopharm Theranostics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways